Quest Diagnostics, provider of diagnostic information and services, announced that hospitals, physicians and patients across India will now be able to broadly access its cancer diagnostic testing services. Quest Diagnostics India has expanded the ability to access cancer diagnostics services following a successful pilot of the introduction of these services to patients and oncologists in New Delhi. Now, the company has expanded its marketing, service and logistics operation in order to provide cancer testing services to 25 metros and Tier-I cities across the country, including Delhi, Mumbai, Bangalore, Kolkata, Hyderabad, Ahmedabad, Kochi. Quest Diagnostics, headquartered in the US, provides services in India through its full service laboratory in Gurgaon, India and esoteric testing laboratories based in the US. Recently introduced services include testing to help detect haematological, or blood, cancers using next-generation sequencing, a technique that identifies mutations and variants in an individual’s DNA or genome. Another service is a test that assesses the ROS1 gene mutation status to help determine a patient’s response to a certain lung cancer therapy. The company also provides testing for breast, cervical, prostate, soft tissue, bone and several other cancers. “The incidence of cancer cases is on the rise in India. Today, patients and the treating physician need accurate and reliable diagnostic insights in order to make the right treatment decision,” said Mukul Bagga, MD, Quest Diagnostics India.“The most exciting and important advances in cancer diagnostics are occurring in the field of genomics and molecular testing. Yet, technology and expertise constraints can limit access by clinicians and patients in India. Clinicians and patients in major cities of India can now access the international experience and clinical operations of Quest Diagnostics, the world leader in diagnostic information services, including cancer testing, in India and the US,” he added.
EH News Bureau